var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F5147453%2Fitems%3Fkey%3DUZ9AvlSPtkFZH6NIkrCwpFLK%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F5147453%2Fitems%3Fkey%3DUZ9AvlSPtkFZH6NIkrCwpFLK%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F5147453%2Fitems%3Fkey%3DUZ9AvlSPtkFZH6NIkrCwpFLK%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
  2. \n
  3. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
  4. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2023\n \n \n (13)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Joint effects of substance use disorders and recent substance use on HIV viral non‐suppression among people engaged in HIV care in an urban clinic, 2014–2019.\n \n \n \n \n\n\n \n Lesko, C. R.; Falade‐Nwulia, O. O.; Pytell, J. D.; Hutton, H. E.; Fojo, A. T.; Keruly, J. C.; Moore, R. D.; and Chander, G.\n\n\n \n\n\n\n Addiction, 118(11): 2193–2202. November 2023.\n \n\n\n\n
\n\n\n\n \n \n \"JointPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{lesko_joint_2023,\n\ttitle = {Joint effects of substance use disorders and recent substance use on {HIV} viral non‐suppression among people engaged in {HIV} care in an urban clinic, 2014–2019},\n\tvolume = {118},\n\tissn = {0965-2140, 1360-0443},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1111/add.16301},\n\tdoi = {10.1111/add.16301},\n\tabstract = {Abstract \n             \n              Aims \n              To estimate the joint effects of substance use disorder (SUD) and recent substance use on human immunodeficiency virus (HIV) non‐suppression. \n             \n             \n              Design \n              Retrospective clinical cohort study with repeated observations within individuals. \n             \n             \n              Setting \n              Baltimore, Maryland, United States. \n             \n             \n              Participants \n              1881 patients contributed 10 794 observations. \n             \n             \n              Measurements \n              The primary independent variable was the combination of history of SUD and recent substance use. History of SUD was defined as any prior International Classification of Diseases 9/10 code for cocaine or opioid disorder. Recent substance use was defined as the self‐report of cocaine or non‐prescribed opioid use on the National Institute of Drug Abuse‐modified Alcohol, Smoking and Substance Involvement Screening Test or clinician‐documented cocaine or opioid use abstracted from the medical record. The outcome was viral non‐suppression, defined as HIV RNA {\\textgreater}200 copies/mL on the first viral load measurement within 1 year subsequent to each observation of substance use. We adjusted for birth sex, Black race, age, HIV acquisition risk factors, years in care and CD4 cell count. In secondary analyses, we also adjusted for depressive, anxiety and panic symptoms, cannabis use and cannabis use disorder. \n             \n             \n              Findings \n              On their first observation, 31\\% of patients had a history of an SUD and 18\\% had recent substance use. Relative to no history of SUD and no recent substance use, the 1‐year fully adjusted risk difference (RD) for viral non‐suppression associated with cocaine and opioid use disorder and recent substance use was 7.7\\% (95\\% CI = 5.3\\%–10.0\\%), the RD was 5.5\\% (95\\% CI = 1.2\\%–9.7\\%) for history of cocaine use disorder without recent substance use, and the RD was 4.6\\% (95\\% CI = 2.7\\%–6.5\\%) for recent substance use without a SUD. \n             \n             \n              Conclusions \n              Substance use and substance use disorders appear to be highly prevalent among, and independently associated with, viral non‐suppression among people with HIV.},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2023-11-09},\n\tjournal = {Addiction},\n\tauthor = {Lesko, Catherine R. and Falade‐Nwulia, Oluwaseun O. and Pytell, Jarratt D. and Hutton, Heidi E. and Fojo, Anthony T. and Keruly, Jeanne C. and Moore, Richard D. and Chander, Geetanjali},\n\tmonth = nov,\n\tyear = {2023},\n\tpages = {2193--2202},\n}\n\n
\n
\n\n\n
\n Abstract Aims To estimate the joint effects of substance use disorder (SUD) and recent substance use on human immunodeficiency virus (HIV) non‐suppression. Design Retrospective clinical cohort study with repeated observations within individuals. Setting Baltimore, Maryland, United States. Participants 1881 patients contributed 10 794 observations. Measurements The primary independent variable was the combination of history of SUD and recent substance use. History of SUD was defined as any prior International Classification of Diseases 9/10 code for cocaine or opioid disorder. Recent substance use was defined as the self‐report of cocaine or non‐prescribed opioid use on the National Institute of Drug Abuse‐modified Alcohol, Smoking and Substance Involvement Screening Test or clinician‐documented cocaine or opioid use abstracted from the medical record. The outcome was viral non‐suppression, defined as HIV RNA \\textgreater200 copies/mL on the first viral load measurement within 1 year subsequent to each observation of substance use. We adjusted for birth sex, Black race, age, HIV acquisition risk factors, years in care and CD4 cell count. In secondary analyses, we also adjusted for depressive, anxiety and panic symptoms, cannabis use and cannabis use disorder. Findings On their first observation, 31% of patients had a history of an SUD and 18% had recent substance use. Relative to no history of SUD and no recent substance use, the 1‐year fully adjusted risk difference (RD) for viral non‐suppression associated with cocaine and opioid use disorder and recent substance use was 7.7% (95% CI = 5.3%–10.0%), the RD was 5.5% (95% CI = 1.2%–9.7%) for history of cocaine use disorder without recent substance use, and the RD was 4.6% (95% CI = 2.7%–6.5%) for recent substance use without a SUD. Conclusions Substance use and substance use disorders appear to be highly prevalent among, and independently associated with, viral non‐suppression among people with HIV.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States.\n \n \n \n \n\n\n \n Fujita, A. W.; Loughry, N.; Moore, D. E; Carter, A. E; Hussen, S. A; Cooper, H.; Colasanti, J. A; and Sheth, A. N\n\n\n \n\n\n\n Clinical Infectious Diseases, 76(7): 1197–1204. April 2023.\n \n\n\n\n
\n\n\n\n \n \n \"Prevalence,Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{fujita_prevalence_2023,\n\ttitle = {Prevalence, {Distribution}, and {Characteristics} {Associated} {With} {Possession} of {Buprenorphine} {Waivers} {Among} {Infectious} {Diseases} {Physicians} in the {United} {States}},\n\tvolume = {76},\n\tissn = {1058-4838, 1537-6591},\n\turl = {https://academic.oup.com/cid/article/76/7/1197/6843761},\n\tdoi = {10.1093/cid/ciac909},\n\tabstract = {Abstract \n             \n              Background \n              Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD. Buprenorphine is safe and effective for OUD but remains underutilized. The prevalence and geographic distribution of ID physicians who are waivered to prescribe buprenorphine are unknown. \n             \n             \n              Methods \n              This cross-sectional study merged data from several publicly available datasets from 1 November 2021 to 15 January 2022. Our primary outcome was the proportion of ID physicians possessing buprenorphine waivers in the United States. We identified individual- and county-level characteristics associated with buprenorphine waiver possession. We then used geospatial analysis to determine the geographic distribution of waivered ID physicians. \n             \n             \n              Results \n              We identified 6372 ID physicians in the United States, among whom 170 (2.7\\%) possessed waivers. Most ID physicians (97.3\\%) practiced in metropolitan counties. In our multivariable analysis, ID physicians had lower odds of having a waiver for every 10-year increase since graduating medical school (OR: .79; 95\\% CI: .68–.91). ID physicians practicing in counties with a higher proportion of uninsured residents had lower odds of having a waiver (OR: .75; 95\\% CI: .62–.90). Among counties with ≥1 ID physician (n = 729), only 11.2\\% had ≥1 waivered ID physician. \n             \n             \n              Conclusions \n              We found an extremely low prevalence and skewed geographic distribution of ID physicians with buprenorphine waivers. Our findings suggest an urgent need to increase the workforce of ID physicians waivered to prescribe buprenorphine and a call for increased integration of OUD education into ID training and continuing medical education.},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2023-11-09},\n\tjournal = {Clinical Infectious Diseases},\n\tauthor = {Fujita, Ayako Wendy and Loughry, Nora and Moore, DeLante E and Carter, Andrea E and Hussen, Sophia A and Cooper, Hannah and Colasanti, Jonathan A and Sheth, Anandi N},\n\tmonth = apr,\n\tyear = {2023},\n\tpages = {1197--1204},\n}\n\n
\n
\n\n\n
\n Abstract Background Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD. Buprenorphine is safe and effective for OUD but remains underutilized. The prevalence and geographic distribution of ID physicians who are waivered to prescribe buprenorphine are unknown. Methods This cross-sectional study merged data from several publicly available datasets from 1 November 2021 to 15 January 2022. Our primary outcome was the proportion of ID physicians possessing buprenorphine waivers in the United States. We identified individual- and county-level characteristics associated with buprenorphine waiver possession. We then used geospatial analysis to determine the geographic distribution of waivered ID physicians. Results We identified 6372 ID physicians in the United States, among whom 170 (2.7%) possessed waivers. Most ID physicians (97.3%) practiced in metropolitan counties. In our multivariable analysis, ID physicians had lower odds of having a waiver for every 10-year increase since graduating medical school (OR: .79; 95% CI: .68–.91). ID physicians practicing in counties with a higher proportion of uninsured residents had lower odds of having a waiver (OR: .75; 95% CI: .62–.90). Among counties with ≥1 ID physician (n = 729), only 11.2% had ≥1 waivered ID physician. Conclusions We found an extremely low prevalence and skewed geographic distribution of ID physicians with buprenorphine waivers. Our findings suggest an urgent need to increase the workforce of ID physicians waivered to prescribe buprenorphine and a call for increased integration of OUD education into ID training and continuing medical education.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Digital Epidemiological Approaches in HIV Research: a Scoping Methodological Review.\n \n \n \n \n\n\n \n Young, L. E.; Nan, Y.; Jang, E.; and Stevens, R.\n\n\n \n\n\n\n Current HIV/AIDS Reports. November 2023.\n \n\n\n\n
\n\n\n\n \n \n \"DigitalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{young_digital_2023,\n\ttitle = {Digital {Epidemiological} {Approaches} in {HIV} {Research}: a {Scoping} {Methodological} {Review}},\n\tissn = {1548-3568, 1548-3576},\n\tshorttitle = {Digital {Epidemiological} {Approaches} in {HIV} {Research}},\n\turl = {https://link.springer.com/10.1007/s11904-023-00673-x},\n\tdoi = {10.1007/s11904-023-00673-x},\n\tabstract = {Abstract \n             \n              Purpose of Review \n              The purpose of this scoping review was to summarize literature regarding the use of user-generated digital data collected for non-epidemiological purposes in human immunodeficiency virus (HIV) research. \n             \n             \n              Recent Findings \n              Thirty-nine papers were included in the final review. Four types of digital data were used: social media data, web search queries, mobile phone data, and data from global positioning system (GPS) devices. With these data, four HIV epidemiological objectives were pursued, including disease surveillance, behavioral surveillance, assessment of public attention to HIV, and characterization of risk contexts. Approximately one-third used machine learning for classification, prediction, or topic modeling. Less than a quarter discussed the ethics of using user-generated data for epidemiological purposes. \n             \n             \n              Summary \n              User-generated digital data can be used to monitor, predict, and contextualize HIV risk and can help disrupt trajectories of risk closer to onset. However, more attention needs to be paid to digital ethics and the direction of the field in a post-Application Programming Interface (API) world.},\n\tlanguage = {en},\n\turldate = {2023-11-09},\n\tjournal = {Current HIV/AIDS Reports},\n\tauthor = {Young, Lindsay E. and Nan, Yuanfeixue and Jang, Eugene and Stevens, Robin},\n\tmonth = nov,\n\tyear = {2023},\n}\n\n
\n
\n\n\n
\n Abstract Purpose of Review The purpose of this scoping review was to summarize literature regarding the use of user-generated digital data collected for non-epidemiological purposes in human immunodeficiency virus (HIV) research. Recent Findings Thirty-nine papers were included in the final review. Four types of digital data were used: social media data, web search queries, mobile phone data, and data from global positioning system (GPS) devices. With these data, four HIV epidemiological objectives were pursued, including disease surveillance, behavioral surveillance, assessment of public attention to HIV, and characterization of risk contexts. Approximately one-third used machine learning for classification, prediction, or topic modeling. Less than a quarter discussed the ethics of using user-generated data for epidemiological purposes. Summary User-generated digital data can be used to monitor, predict, and contextualize HIV risk and can help disrupt trajectories of risk closer to onset. However, more attention needs to be paid to digital ethics and the direction of the field in a post-Application Programming Interface (API) world.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Increasing overdose deaths among Black Americans: a review of the literature.\n \n \n \n \n\n\n \n Gibbons, J. B; Harris, S. J; Solomon, K. T; Sugarman, O.; Hardy, C.; and Saloner, B.\n\n\n \n\n\n\n The Lancet Psychiatry, 10(9): 719–726. September 2023.\n \n\n\n\n
\n\n\n\n \n \n \"IncreasingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{gibbons_increasing_2023,\n\ttitle = {Increasing overdose deaths among {Black} {Americans}: a review of the literature},\n\tvolume = {10},\n\tissn = {22150366},\n\tshorttitle = {Increasing overdose deaths among {Black} {Americans}},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2215036623001190},\n\tdoi = {10.1016/S2215-0366(23)00119-0},\n\tlanguage = {en},\n\tnumber = {9},\n\turldate = {2023-11-09},\n\tjournal = {The Lancet Psychiatry},\n\tauthor = {Gibbons, Jason B and Harris, Samantha J and Solomon, Keisha T and Sugarman, Olivia and Hardy, Carlos and Saloner, Brendan},\n\tmonth = sep,\n\tyear = {2023},\n\tpages = {719--726},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Disentangling opioids-related overdose syndemics: a scoping review.\n \n \n \n \n\n\n \n Lang, J.; Mendenhall, E.; and Koon, A. D.\n\n\n \n\n\n\n International Journal of Drug Policy, 119: 104152. September 2023.\n \n\n\n\n
\n\n\n\n \n \n \"DisentanglingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{lang_disentangling_2023,\n\ttitle = {Disentangling opioids-related overdose syndemics: a scoping review},\n\tvolume = {119},\n\tissn = {09553959},\n\tshorttitle = {Disentangling opioids-related overdose syndemics},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0955395923001998},\n\tdoi = {10.1016/j.drugpo.2023.104152},\n\tlanguage = {en},\n\turldate = {2023-11-09},\n\tjournal = {International Journal of Drug Policy},\n\tauthor = {Lang, Jake and Mendenhall, Emily and Koon, Adam D.},\n\tmonth = sep,\n\tyear = {2023},\n\tpages = {104152},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.\n \n \n \n \n\n\n \n Degenhardt, L.; Webb, P.; Colledge-Frisby, S.; Ireland, J.; Wheeler, A.; Ottaviano, S.; Willing, A.; Kairouz, A.; Cunningham, E. B; Hajarizadeh, B.; Leung, J.; Tran, L. T; Price, O.; Peacock, A.; Vickerman, P.; Farrell, M.; Dore, G. J; Hickman, M.; and Grebely, J.\n\n\n \n\n\n\n The Lancet Global Health, 11(5): e659–e672. May 2023.\n \n\n\n\n
\n\n\n\n \n \n \"EpidemiologyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{degenhardt_epidemiology_2023,\n\ttitle = {Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review},\n\tvolume = {11},\n\tissn = {2214109X},\n\tshorttitle = {Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2214109X23000578},\n\tdoi = {10.1016/S2214-109X(23)00057-8},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2023-11-09},\n\tjournal = {The Lancet Global Health},\n\tauthor = {Degenhardt, Louisa and Webb, Paige and Colledge-Frisby, Samantha and Ireland, Jeremy and Wheeler, Alice and Ottaviano, Sophie and Willing, Alex and Kairouz, Abe and Cunningham, Evan B and Hajarizadeh, Behzad and Leung, Janni and Tran, Lucy T and Price, Olivia and Peacock, Amy and Vickerman, Peter and Farrell, Michael and Dore, Gregory J and Hickman, Matthew and Grebely, Jason},\n\tmonth = may,\n\tyear = {2023},\n\tpages = {e659--e672},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.\n \n \n \n \n\n\n \n Person, A. K; Armstrong, W. S; Evans, T.; Fangman, J. J W; Goldstein, R. H; Haddad, M.; Jain, M. K; Keeshin, S.; Tookes, H. E; Weddle, A. L; and Feinberg, J.\n\n\n \n\n\n\n Clinical Infectious Diseases, 76(1): 1–9. January 2023.\n \n\n\n\n
\n\n\n\n \n \n \"PrinciplesPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{person_principles_2023,\n\ttitle = {Principles for {Ending} {Human} {Immunodeficiency} {Virus} as an {Epidemic} in the {United} {States}: {A} {Policy} {Paper} of the {Infectious} {Diseases} {Society} of {America} and the {HIV} {Medicine} {Association}},\n\tvolume = {76},\n\tissn = {1058-4838, 1537-6591},\n\tshorttitle = {Principles for {Ending} {Human} {Immunodeficiency} {Virus} as an {Epidemic} in the {United} {States}},\n\turl = {https://academic.oup.com/cid/article/76/1/1/6662275},\n\tdoi = {10.1093/cid/ciac626},\n\tabstract = {Abstract \n            While we have the tools to achieve this goal, the persistent barriers to healthcare services experienced by too many individuals will need to be addressed to make significant progress and improve the health and quality of life of all people with human immunodeficiency virus (HIV). The necessary structural changes require actions by federal, state, and local policymakers and range from ensuring universal access to healthcare services to optimizing care delivery to ensuring a robust and diverse infectious diseases and HIV workforce. In this article, we outlines 10 key principles for policy reforms that, if advanced, would make ending the HIV epidemic in the United States possible and could have much more far-reaching effects in improving the health of our nation.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2023-11-09},\n\tjournal = {Clinical Infectious Diseases},\n\tauthor = {Person, Anna K and Armstrong, Wendy S and Evans, Tyler and Fangman, John J W and Goldstein, Robert H and Haddad, Marwan and Jain, Mamta K and Keeshin, Susana and Tookes, Hansel E and Weddle, Andrea L and Feinberg, Judith},\n\tmonth = jan,\n\tyear = {2023},\n\tpages = {1--9},\n}\n\n
\n
\n\n\n
\n Abstract While we have the tools to achieve this goal, the persistent barriers to healthcare services experienced by too many individuals will need to be addressed to make significant progress and improve the health and quality of life of all people with human immunodeficiency virus (HIV). The necessary structural changes require actions by federal, state, and local policymakers and range from ensuring universal access to healthcare services to optimizing care delivery to ensuring a robust and diverse infectious diseases and HIV workforce. In this article, we outlines 10 key principles for policy reforms that, if advanced, would make ending the HIV epidemic in the United States possible and could have much more far-reaching effects in improving the health of our nation.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV.\n \n \n \n \n\n\n \n Tusch, E. S.; Ryom, L.; Fursa, O.; Peters, L.; Østergaard, L.; Florence, E.; Edwards, S.; Hoffmann, C.; Sambatakou, H.; Reiss, P.; Shahar, E.; Reikvam, D. H.; Schmied, B.; Paduta, D.; Yakovlev, A.; Szlávik, J.; Ranin, J.; Zilmer, K.; Uždaviniene, V.; Pelchen-Matthews, A.; Mocroft, A.; and Reekie, J.\n\n\n \n\n\n\n AIDS, 37(1): 161–171. January 2023.\n \n\n\n\n
\n\n\n\n \n \n \"IncidencePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{tusch_incidence_2023,\n\ttitle = {Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with {HIV}},\n\tvolume = {37},\n\tissn = {0269-9370, 1473-5571},\n\turl = {https://journals.lww.com/10.1097/QAD.0000000000003402},\n\tdoi = {10.1097/QAD.0000000000003402},\n\tabstract = {Objective: \n               \n                Deaths due to suicide, substance use and violence/accident may reflect similar risk factors and overlap in their classification. This study aimed \n                 \n                to investigate incidence and risk factors of mortality among people with HIV (PWH) due to these three related causes. \n               \n             \n             \n              Design: \n              Prospectively collected data from PWH at least 18 years old and under active follow-up in the EuroSIDA study from 2007 to 2019 were analysed. \n             \n             \n              Methods: \n              Cause-specific Cox regression analysis was used to assess risk factors. \n             \n             \n              Results: \n              A total of 17 881 participants were included, comprising 149 327 person-years of follow-up (PYFU). Forty participants died by suicide \\{incidence rate [IR] [95\\% confidence interval (CI)]: 0.3/1000 PYFU (0.2, 0.4)\\} 93 from substance use [IR (95\\% CI): 0.6/1000 PYFU (0.5, 0.8)], and 57 by violence/accident [IR (95\\% CI): 0.4/1000 PYFU (0.3, 0.5)]. An AIDS diagnosis within the last 12 months was associated with nine-fold increased risk of suicide vs. no history of AIDS [adjusted hazard ratio (aHR): 9.06; 95\\% CI: 2.07, 39.7]. Male gender was associated with double the risk of violent/accidental death (aHR: 2.28; 95\\% CI: 1.09, 4.78). PWH in Eastern Europe and those who acquired HIV by injection drug use (IDU) demonstrated a greater risk of death due to substance use or violence/accident. \n             \n             \n              Conclusions: \n              The association between a recent diagnosis of AIDS and suicide highlights a critical period for intervention. HIV infection acquired through IDU demonstrated an expected relationship with death due to substance use and violent/accidental deaths. Increased risk of death due to substance use and violence/accident in Eastern Europe demands investigation into specific differences that may drive that association.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2023-11-09},\n\tjournal = {AIDS},\n\tauthor = {Tusch, Erich S. and Ryom, Lene and Fursa, Olga and Peters, Lars and Østergaard, Lars and Florence, Eric and Edwards, Simon and Hoffmann, Christian and Sambatakou, Helen and Reiss, Peter and Shahar, Eduardo and Reikvam, Dag Henrik and Schmied, Brigitte and Paduta, Dzmitry and Yakovlev, Alexei and Szlávik, János and Ranin, Jovan and Zilmer, Kai and Uždaviniene, Vilma and Pelchen-Matthews, Annegret and Mocroft, Amanda and Reekie, Joanne},\n\tmonth = jan,\n\tyear = {2023},\n\tpages = {161--171},\n}\n\n
\n
\n\n\n
\n Objective: Deaths due to suicide, substance use and violence/accident may reflect similar risk factors and overlap in their classification. This study aimed to investigate incidence and risk factors of mortality among people with HIV (PWH) due to these three related causes. Design: Prospectively collected data from PWH at least 18 years old and under active follow-up in the EuroSIDA study from 2007 to 2019 were analysed. Methods: Cause-specific Cox regression analysis was used to assess risk factors. Results: A total of 17 881 participants were included, comprising 149 327 person-years of follow-up (PYFU). Forty participants died by suicide \\incidence rate [IR] [95% confidence interval (CI)]: 0.3/1000 PYFU (0.2, 0.4)\\ 93 from substance use [IR (95% CI): 0.6/1000 PYFU (0.5, 0.8)], and 57 by violence/accident [IR (95% CI): 0.4/1000 PYFU (0.3, 0.5)]. An AIDS diagnosis within the last 12 months was associated with nine-fold increased risk of suicide vs. no history of AIDS [adjusted hazard ratio (aHR): 9.06; 95% CI: 2.07, 39.7]. Male gender was associated with double the risk of violent/accidental death (aHR: 2.28; 95% CI: 1.09, 4.78). PWH in Eastern Europe and those who acquired HIV by injection drug use (IDU) demonstrated a greater risk of death due to substance use or violence/accident. Conclusions: The association between a recent diagnosis of AIDS and suicide highlights a critical period for intervention. HIV infection acquired through IDU demonstrated an expected relationship with death due to substance use and violent/accidental deaths. Increased risk of death due to substance use and violence/accident in Eastern Europe demands investigation into specific differences that may drive that association.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Past-year medical and non-medical opioid use by HIV status in a nationally representative US sample: Implications for HIV and substance use service integration.\n \n \n \n \n\n\n \n West, B. S.; Diaz, J. E.; Philbin, M. M.; and Mauro, P. M.\n\n\n \n\n\n\n Journal of Substance Use and Addiction Treatment, 147: 208976. April 2023.\n \n\n\n\n
\n\n\n\n \n \n \"Past-yearPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{west_past-year_2023,\n\ttitle = {Past-year medical and non-medical opioid use by {HIV} status in a nationally representative {US} sample: {Implications} for {HIV} and substance use service integration},\n\tvolume = {147},\n\tissn = {29498759},\n\tshorttitle = {Past-year medical and non-medical opioid use by {HIV} status in a nationally representative {US} sample},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2949875923000267},\n\tdoi = {10.1016/j.josat.2023.208976},\n\tlanguage = {en},\n\turldate = {2023-11-09},\n\tjournal = {Journal of Substance Use and Addiction Treatment},\n\tauthor = {West, Brooke S. and Diaz, José E. and Philbin, Morgan M. and Mauro, Pia M.},\n\tmonth = apr,\n\tyear = {2023},\n\tpages = {208976},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Age group differences in substance use, social support, and physical and mental health concerns among people living with HIV two years after receiving primary care-based alcohol treatment.\n \n \n \n \n\n\n \n Satre, D. D.; Sarovar, V.; Leyden, W. A.; Leibowitz, A. S.; Lam, J. O.; Hojilla, J. C.; Davy-Mendez, T.; Hare, C. B.; and Silverberg, M. J.\n\n\n \n\n\n\n Aging & Mental Health, 27(5): 1011–1019. May 2023.\n \n\n\n\n
\n\n\n\n \n \n \"AgePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{satre_age_2023,\n\ttitle = {Age group differences in substance use, social support, and physical and mental health concerns among people living with {HIV} two years after receiving primary care-based alcohol treatment},\n\tvolume = {27},\n\tissn = {1360-7863, 1364-6915},\n\turl = {https://www.tandfonline.com/doi/full/10.1080/13607863.2022.2084504},\n\tdoi = {10.1080/13607863.2022.2084504},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2023-11-09},\n\tjournal = {Aging \\& Mental Health},\n\tauthor = {Satre, Derek D. and Sarovar, Varada and Leyden, Wendy A. and Leibowitz, Amy S. and Lam, Jennifer O. and Hojilla, J. Carlo and Davy-Mendez, Thibaut and Hare, Charles B. and Silverberg, Michael J.},\n\tmonth = may,\n\tyear = {2023},\n\tpages = {1011--1019},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Chronic pain and substance use disorders among older sexual minority men living with HIV: Implications for HIV disease management across the HIV care continuum.\n \n \n \n \n\n\n \n Taylor, S. W.; McKetchnie, S. M.; Batchelder, A. W.; Justice, A.; Safren, S. A.; and O’Cleirigh, C.\n\n\n \n\n\n\n AIDS Care, 35(4): 614–623. April 2023.\n \n\n\n\n
\n\n\n\n \n \n \"ChronicPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{taylor_chronic_2023,\n\ttitle = {Chronic pain and substance use disorders among older sexual minority men living with {HIV}: {Implications} for {HIV} disease management across the {HIV} care continuum},\n\tvolume = {35},\n\tissn = {0954-0121, 1360-0451},\n\tshorttitle = {Chronic pain and substance use disorders among older sexual minority men living with {HIV}},\n\turl = {https://www.tandfonline.com/doi/full/10.1080/09540121.2022.2076801},\n\tdoi = {10.1080/09540121.2022.2076801},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2023-11-09},\n\tjournal = {AIDS Care},\n\tauthor = {Taylor, S. Wade and McKetchnie, Samantha M. and Batchelder, Abigail W. and Justice, Amy and Safren, Steven A. and O’Cleirigh, Conall},\n\tmonth = apr,\n\tyear = {2023},\n\tpages = {614--623},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Characterizing the Development of Research Landscapes in Substance Use and HIV/AIDS During 1990 to 2021.\n \n \n \n \n\n\n \n Nguyen, T. T.; Nguyen, H. T.; Do, H. P.; Ho, C. S.; and Ho, R. C.\n\n\n \n\n\n\n Substance Abuse: Research and Treatment, 17: 117822182311775. January 2023.\n \n\n\n\n
\n\n\n\n \n \n \"CharacterizingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{nguyen_characterizing_2023,\n\ttitle = {Characterizing the {Development} of {Research} {Landscapes} in {Substance} {Use} and {HIV}/{AIDS} {During} 1990 to 2021},\n\tvolume = {17},\n\tissn = {1178-2218, 1178-2218},\n\turl = {http://journals.sagepub.com/doi/10.1177/11782218231177515},\n\tdoi = {10.1177/11782218231177515},\n\tabstract = {Mitigating the impacts of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and substance use requires comprehensive and systematic thinking in designing interventions and developing policies. This study describes the growth of research publications from 1991 to 2021 in the Web of Science database and points out current research landscapes in the fields of HIV/AIDS and substance use. Latent Dirichlet Allocation was used for classifying 21 359 papers into corresponding topics. The most common topics were HIV transmission, HIV infection, quality of life and mental health of substance users, and the biomedical effect of substance use. Emerging research landscapes include vulnerabilities of people who inject drugs to HIV transmission and related health problems. This study found a lack of research on health services, interdisciplinary and inter-sectoral in combination with clinical evaluation and treatment services. Future investment and implementation of HIV/AIDS and substance use programs should focus on research of health services and clinical evaluation, especially context-specific interventions.},\n\tlanguage = {en},\n\turldate = {2023-11-09},\n\tjournal = {Substance Abuse: Research and Treatment},\n\tauthor = {Nguyen, Tham Thi and Nguyen, Hien Thu and Do, Huyen Phuc and Ho, Cyrus Sh and Ho, Roger Cm},\n\tmonth = jan,\n\tyear = {2023},\n\tpages = {117822182311775},\n}\n\n
\n
\n\n\n
\n Mitigating the impacts of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and substance use requires comprehensive and systematic thinking in designing interventions and developing policies. This study describes the growth of research publications from 1991 to 2021 in the Web of Science database and points out current research landscapes in the fields of HIV/AIDS and substance use. Latent Dirichlet Allocation was used for classifying 21 359 papers into corresponding topics. The most common topics were HIV transmission, HIV infection, quality of life and mental health of substance users, and the biomedical effect of substance use. Emerging research landscapes include vulnerabilities of people who inject drugs to HIV transmission and related health problems. This study found a lack of research on health services, interdisciplinary and inter-sectoral in combination with clinical evaluation and treatment services. Future investment and implementation of HIV/AIDS and substance use programs should focus on research of health services and clinical evaluation, especially context-specific interventions.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Structural Equation Modeling of Stigma and HIV Prevention Clinical Services Among Transgender and Gender Diverse Adults: The Mediating Role of Substance Use and HIV Sexual Risk.\n \n \n \n \n\n\n \n Wolfe, H. L.; Drainoni, M.; Klasko-Foster, L.; Fix, G. M.; Siegel, J.; Mimiaga, M. J.; Reisner, S. L.; and Hughto, J. M.\n\n\n \n\n\n\n JAIDS Journal of Acquired Immune Deficiency Syndromes, 92(4): 300–309. April 2023.\n \n\n\n\n
\n\n\n\n \n \n \"StructuralPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{wolfe_structural_2023,\n\ttitle = {Structural {Equation} {Modeling} of {Stigma} and {HIV} {Prevention} {Clinical} {Services} {Among} {Transgender} and {Gender} {Diverse} {Adults}: {The} {Mediating} {Role} of {Substance} {Use} and {HIV} {Sexual} {Risk}},\n\tvolume = {92},\n\tissn = {1525-4135},\n\tshorttitle = {Structural {Equation} {Modeling} of {Stigma} and {HIV} {Prevention} {Clinical} {Services} {Among} {Transgender} and {Gender} {Diverse} {Adults}},\n\turl = {https://journals.lww.com/10.1097/QAI.0000000000003144},\n\tdoi = {10.1097/QAI.0000000000003144},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2023-08-14},\n\tjournal = {JAIDS Journal of Acquired Immune Deficiency Syndromes},\n\tauthor = {Wolfe, Hill L. and Drainoni, Mari-Lynn and Klasko-Foster, Lynne and Fix, Gemmae M. and Siegel, Jennifer and Mimiaga, Matthew J. and Reisner, Sari L. and Hughto, Jaclyn M.W.},\n\tmonth = apr,\n\tyear = {2023},\n\tpages = {300--309},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017.\n \n \n \n \n\n\n \n Parcesepe, A. M.; Lancaster, K.; Edelman, E. J.; DeBoni, R.; Ross, J.; Atwoli, L.; Tlali, M.; Althoff, K.; Tine, J.; Duda, S. N.; Wester, C. W.; Nash, D.; and for the IeDEA Consortium\n\n\n \n\n\n\n PLOS ONE, 15(8): e0237772. August 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SubstancePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{parcesepe_substance_2020,\n\ttitle = {Substance use service availability in {HIV} treatment programs: {Data} from the global {IeDEA} consortium, 2014-2015 and 2017},\n\tvolume = {15},\n\tissn = {1932-6203},\n\tshorttitle = {Substance use service availability in {HIV} treatment programs},\n\turl = {https://dx.plos.org/10.1371/journal.pone.0237772},\n\tdoi = {10.1371/journal.pone.0237772},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2023-08-14},\n\tjournal = {PLOS ONE},\n\tauthor = {Parcesepe, Angela M. and Lancaster, Kathryn and Edelman, E. Jennifer and DeBoni, Raquel and Ross, Jeremy and Atwoli, Lukoye and Tlali, Mpho and Althoff, Keri and Tine, Judicaël and Duda, Stephany N. and Wester, C. William and Nash, Denis and {for the IeDEA Consortium}},\n\teditor = {Francis, Joel Msafiri},\n\tmonth = aug,\n\tyear = {2020},\n\tpages = {e0237772},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States: Food insecurity and substance use in the US.\n \n \n \n \n\n\n \n Whittle, H. J.; Sheira, L. A.; Frongillo, E. A.; Palar, K.; Cohen, J.; Merenstein, D.; Wilson, T. E.; Adedimeji, A.; Cohen, M. H.; Adimora, A. A.; Ofotokun, I.; Metsch, L.; Turan, J. M.; Wentz, E. L.; Tien, P. C.; and Weiser, S. D.\n\n\n \n\n\n\n Addiction, 114(1): 127–136. January 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LongitudinalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{whittle_longitudinal_2019,\n\ttitle = {Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for {HIV} in the {United} {States}: {Food} insecurity and substance use in the {US}},\n\tvolume = {114},\n\tissn = {09652140},\n\tshorttitle = {Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for {HIV} in the {United} {States}},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1111/add.14418},\n\tdoi = {10.1111/add.14418},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2023-08-14},\n\tjournal = {Addiction},\n\tauthor = {Whittle, Henry J. and Sheira, Lila A. and Frongillo, Edward A. and Palar, Kartika and Cohen, Jennifer and Merenstein, Daniel and Wilson, Tracey E. and Adedimeji, Adebola and Cohen, Mardge H. and Adimora, Adaora A. and Ofotokun, Ighovwerha and Metsch, Lisa and Turan, Janet M. and Wentz, Eryka L. and Tien, Phyllis C. and Weiser, Sheri D.},\n\tmonth = jan,\n\tyear = {2019},\n\tpages = {127--136},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);